[EN] SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS<br/>[FR] INHIBITEURS DE KINASE D'ADHÉSION FOCALE À PETITES MOLÉCULES (FAK)
申请人:DANA FARBER CANCER INST INC
公开号:WO2020231726A1
公开(公告)日:2020-11-19
Disclosed are compounds that possess inhibitory activity against FAK. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat cancer mediated by aberrant FAK activity.
CORRAO, STEPHANIE L.;MACIELAG, MARK J.;TURCHI, IGNATIUS J., J. ORG. CHEM., 55,(1990) N4, C. 4484-4487
作者:CORRAO, STEPHANIE L.、MACIELAG, MARK J.、TURCHI, IGNATIUS J.
DOI:——
日期:——
Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor
作者:Brian J. Groendyke、Behnam Nabet、Mikaela L. Mohardt、Haisheng Zhang、Ke Peng、Eriko Koide、Calvin R. Coffey、Jianwei Che、David A. Scott、Adam J. Bass、Nathanael S. Gray
DOI:10.1021/acsmedchemlett.0c00338
日期:2021.1.14
Focal adhesion kinase (FAK) is a tyrosine kinase with prominent roles in protein scaffolding, migration, angiogenesis, and anchorage-independent cell survival and is an attractive target for the development of cancer therapeutics. However, current FAK inhibitors display dual kinase inhibition and/or significant activity on several kinases. Although multitargeted activity is at times therapeutically